CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade Federal de São Paulo (UNIFESP). Campus Diadema. Instituto de Ciências Ambientais, Químicas e Farmacêuticas (ICAQF) (Institutional affiliation from the last research proposal) Birthplace: Brazil
João Paulo dos Santos Fernandes holds a BS in Pharmacy from Guarulhos University (2003). He got his MSc degree at the Faculty of Pharmaceutical Sciences, University of São Paulo (2006) in #8203;#8203;Medicinal Chemistry, working on prodrugs with tuberculostatic activity, and his PhD degree in the same University (FCF / USP - 2012) working on synthesis and development of histaminergic and serotonin receptor ligands. He has worked in several universities in São Paulo, and currently is full-time professor at Federal University of São Paulo (UNIFESP), dedicated to Medicinal Chemistry in the Pharmacy course as well as graduate programs in Pharmaceutical Sciences and Translational Medicine.Develops research projects with design, synthesis and evaluation of novel bioactive compounds in the central nervous system, inflammatory and infectious/neglected diseases. Member of the European Histamine Research Society (EHRS) and Brazilian Association of Pharmaceutical Sciences (ABCF). He is referee of several international journals and member of the editorial board of the journals Pharmaceutics and Journal of Tuberculosis Research. He heads the group of Synthesis of Bioactive Molecules (SiMBio), from the Laboratory of Natural and Synthetic Inputs (LINS) of UNIFESP. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The cerebral mechanism related to the control of several neurological disorders (especially Alzheimer's and Parkinson's diseases, affective and mood disorders) are complex and diverse. This heterogeneous nature suggests that the multitarget approach can be the most appropriate in the treatment of such conditions, since it can interfere with more than one target simultaneously and provide …
Aging is generally associated with a certain cognitive decline. Although individual differences exist, the mechanisms underlying learning and memory processes are complex and commonly explored in the search for targets to drug therapy. Certain pathological conditions, such as Alzehimer's and Parkinson's diseases, vascular dementia and mood and affective disorders affect cognition. Conside…
(Only some records are available in English at this moment)
The design of molecules able to interact with more than one target simultaneously has been explored as a strategy in the treatment of complex diseases, such as neurodegenerative diseases, in which different pathophysiological mechanisms are involved. Many neurodegenerative diseases, such as Alzheimer's disease, dementia with Lewy bodies, among others, are characterized by the accumulation…
Melanin is the main biological pigment involved in skin pigmentation that, due to its antioxidant properties, protects against possible damage caused by ultraviolet rays. However, melanin is also produced in the CNS and by other organisms than animals, such as fungi and plants. Melanogenesis is a bioprocess that occurs from phenolic substrates such as L-tyrosine, L-DOPA and dopamine itsel…
The interest in multi-target drugs, i.e., molecules capable of interacting in more than one target simultaneously, has been growing in recent years as a new way to treat complex diseases, which involve different signaling pathways, connected to each other. This is the case for neurodegenerative diseases (for example, Alzheimer's disease), which involve changes in cognition-related pathway…
Interest in multimarket drugs, i.e. molecules capable of interacting with more than one target simultaneously, has been growing in recent years as a new strategy to treat complex diseases that involve different interconnected signaling pathways. This is the case for neuropsychiatric diseases such as Alzheimer's (AD) and Parkinson's diseases, schizophrenia, depression, epilepsy among other…
(Only some records are available in English at this moment)
The discovery and development pipeline for new drug candidates is a challenging process, especially when considering compounds designed to simultaneously act on two or more targets. In this context, two set of compounds were designed and prepared as histamine H3 receptor (H3R) antagonists and glutaminyl cyclase (QC) inhibitors, two targets for therapeutic applications in neurodegenerative…
The current available treatmentfor Chagas' disease is poorly effective during the chronic phase, is relatively toxic and long-lasting. In the search for a more tolerable, effective and affordable drug to the patientsthe LINS03 series has been developed by our group during the past five years as antiparasitic agents, and to datemore than 50 compounds have already been synthesized and evalu…
| 4 / 4 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 11 / 9 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 1 / 1 | Completed scholarships abroad |
| 18 / 16 | All research grants and scholarships |
| Associated processes | |